Oral Biologics & Biosimilar Drugs Global Market Report 2023
Report Highlights
Including: 1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma; Crohn'S Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis
3) By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Novartis; Rani Therapeutics; Eli Lilly and Co.; AstraZeneca plc; Novo Nordisk A/S
Oral Biologics & Biosimilar Drugs Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on oral biologics & biosimilar drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for oral biologics & biosimilar drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral biologics & biosimilar drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2022 |
| Forecast period considered | 2022-2032 |
| Units considered | $ Billion |
| Segments covered | By Therapy, By Disease, By Molecule Type, By Distribution Channel |
| Industry covered | Pharmaceuticals |
| Regions covered | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Countries covered | Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. |
| Companies studied |
|
Scope
Markets Covered:
- By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
- By Disease: Asthma; Crohn'S Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others
- By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Other Molecule Types
- By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Novartis; Rani Therapeutics; Eli Lilly and Co.; AstraZeneca plc; Novo Nordisk A/S
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
- Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
- Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
- Table 3 : Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 4 : Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 5 : Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 6 : Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 7 : Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 8 : Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 9 : Asia-Pacific, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 10 : China, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 11 : India, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 12 : Japan, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 13 : Australia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 14 : Indonesia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 15 : South Korea, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 16 : Western Europe, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 17 : UK, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 18 : Germany, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 19 : France, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 20 : Eastern Europe, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 21 : Russia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 22 : North America, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 23 : USA, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 24 : South America, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 25 : Brazil, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 26 : Middle East, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 27 : Africa, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 28 : Novartis Financial Performance
- Table 29 : Rani Therapeutics Financial Performance
- Table 30 : Eli Lilly and Co. Financial Performance
- Table 31 : AstraZeneca plc Financial Performance
- Table 32 : Novo Nordisk A/S Financial Performance
- Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
- Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
- Figure 3 : Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 4 : Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 5 : Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 6 : Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 7 : Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 8 : Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 9 : Asia-Pacific, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 10 : China, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 11 : India, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 12 : Japan, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 13 : Australia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 14 : Indonesia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 15 : South Korea, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 16 : Western Europe, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 17 : UK, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 18 : Germany, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 19 : France, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 20 : Eastern Europe, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 21 : Russia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 22 : North America, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 23 : USA, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 24 : South America, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 25 : Brazil, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 26 : Middle East, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 27 : Africa, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 28 : Novartis Financial Performance
- Figure 29 : Rani Therapeutics Financial Performance
- Figure 30 : Eli Lilly and Co. Financial Performance
- Figure 31 : AstraZeneca plc Financial Performance
- Figure 32 : Novo Nordisk A/S Financial Performance
The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Similar Reports from TBRC (Publisher)
Oral Biologics & Biosimilars Global Market Report 2022
Including: 1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma; Crohn's Disease, Carcinoma; Arthritis, Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis
3) By Molecule Type: Vaccines; Proteins and Peptides; Monoclonal Antibodies
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Novartis; Rani Therapeutics; Eli Lilly and Co; AstraZeneca plc; Novo ...
Oral Biologics & Biosimilar Drugs Global Market Report 2022
Including: 1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma; Crohn'S Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others
3) By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Others
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Covering: Novartis; Rani Therapeutics; Eli Lilly and ...
Oral Biologics & Biosimilar Drugs Global Market Report 2021: COVID 19 Growth And Change to 2030
Including: 1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma; Crohn'S Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others
3) By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Others
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Novartis; Rani Therapeutics; Eli Lilly and Co.; AstraZeneca ...
Oral Biologics & Biosimilars Global Market Opportunities And Strategies To 2030
Including: By Disease: Diabetes; Arthritis & Chron's Disease; Cancer; Infectious Diseases; Other Autoimmune Disease; Others Diseases
By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Others
By Therapeutic Mechanism: TNF-Alpha; Lymphocyte Modulators; Interleukin Inhibitors; GPCR; Immunostimulants; Others
By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Merck & Co.; GlaxoSmithKline; Novo Nordisk; ALK-Abello A/S; Aimmune Therapeutics, Inc.
Oral ...
Oral Biologics & Biosimilars Market Global Report 2020-30
Including: 1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors; 2) By Disease: Asthma; Crohn'S Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others
Covering: Novartis; Rani Therapeutics; Eli Lilly and Co.; AstraZeneca plc; Novo Nordisk A/S